Synapse Alterations in MSA Patients

Central South University

Status: Completed

Conditions: Multiple System Atrophy

Treatments: Diagnostic Test: [18F]SynVesT-1 PET/CT

Study type: Observational

Funder types: Other

Identifiers

NCT06221644

20240113

Details and patient eligibility

About

Synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (MSA) remains limited.

The aim of this study was to examine spatial synaptic density alterations in MSA patients and evaluate the potential of [18F]SynVesT-1 PET as an imaging biomarker for MSA in both diagnosis and monitoring disease severity.

Full description

60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent [18F]SynVesT-1 PET/CT for synaptic density assessment. Visual, voxel, and volumetric region-of-interest (VOI) analyses were employed to elucidate synaptic density patterns in the MSA brain and establish visual diagnostic criteria. VOI-based computer-assisted analyses were utilized to develop diagnostic models for MSA.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The MSA patient were diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists.

Exclusion criteria

encompassed MRI contraindications, a history of epilepsy, stroke, or brain surgery, intracranial organic lesions unrelated to MSA, usage of levetiracetam or brivaracetam, and a history of alcohol or drug abuse

Trial design

90 participants in 2 patient groups

MSA patients group

Description:

The patient cohort consisted of 30 MSA-C and 30 MSA-P cases, diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists

Treatment:

Diagnostic Test: [18F]SynVesT-1 PET/CT

healthy controls (HCs) group

Description:

30 gender and age-matched HCs were included

Treatment:

Diagnostic Test: [18F]SynVesT-1 PET/CT